Answer
In adults, fingolimod’s average apparent terminal elimination half-life is 6–9 days; it is unchanged with mild hepatic impairment but prolonged by about 50% with moderate or severe hepatic impairment.
Sources for this answer
- Gilenya 0.25mg and 0.5mg hard capsulesNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 37Document updated
Sources checked